Parmodulins with Low Abuse Potential for Neuropathic Pain
Official title: Parmodulins without Abuse Potential for the Treatment of Neuropathic Pain
Funded at Function Therapeutics, INC. · NIH-11415152 · Data updated 2026-11-12
A new class of pain medicines called parmodulins is being studied to help people with nerve-pain pain without high abuse risk.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Function Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | September 11, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $200,070 |
| NIH project number | 5R43NS143450-02 |
| Project ID | NIH-11415152 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with neuropathic pain who may benefit from new, non-addictive analgesics.
✕Less likely to help
People whose pain is not driven by inflammatory signaling or who require non-analgesic pain management.
What this research studies
This project aims to develop parmodulin drugs that modify PAR1 signaling to reduce nerve-pain inflammation and damage. The study focuses on how these drugs can shift inflammatory pathways toward safer, protective effects. Researchers will use early-phase experiments to understand dosing, safety, and how well the drugs work in models related to neuropathic pain.
Why it matters
Potential benefit: If successful, this work could lead to safer, non-addictive options for neuropathic pain relief.
How similar studies have gone: Related approaches with similar signaling bias have shown promise in preclinical models, but human data are needed.
Where this research is happening
-
Function Therapeutics, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Dockendorff, Christopher — Function Therapeutics, INC.
- Study coordinator: Dockendorff, Christopher
Related research
Other NIH-funded projects on the same topics.
-
Peripheral nerve stimulation for chronic neuropathic pain in a new mechanistic trial
A study at Stanford tests whether a painless-sounding electrical nerve treatment helps people with long-standing neuropathic pain when added to standard care.
-
Keratinocytes and nerve pain in chemotherapy patients
A study tests a new approach to reduce painful nerve damage from chemotherapy by targeting skin cells called keratinocytes.
-
High-frequency brain stimulation for trigeminal neuropathic pain
A large, multi-site trial tests a non-invasive brain stimulation method to relieve chronic facial nerve pain for adults who have not found relief from other treatments.
-
Programmable lithium-delivery devices for pain relief without motor loss
A new bioelectronic system uses a safe lithium source and AI-powered control to deliver targeted pain relief for neuropathic pain, aiming to spare motor function.
-
Glial-nerve conversations in neuropathic pain and diabetes
This grant looks at how supportive brain and nerve cells communicate with pain-sensing neurons to understand and reduce chronic nerve pain in people.
-
Nonopioid peptide therapy to reset nerve pain biology
A new, first‑in‑class peptide medicine (ASCT‑83) is being developed to target the biology of neuropathic pain in adults, with early human testing planned after successful preclinical work.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.